BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26618281)

  • 1. The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells.
    Gawlik-Rzemieniewska N; Bednarek I
    Cancer Biol Ther; 2016; 17(1):1-10. PubMed ID: 26618281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer.
    Yao C; Su L; Shan J; Zhu C; Liu L; Liu C; Xu Y; Yang Z; Bian X; Shao J; Li J; Lai M; Shen J; Qian C
    Stem Cells; 2016 Apr; 34(4):820-31. PubMed ID: 26840943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
    Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
    PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.
    Chiou SH; Wang ML; Chou YT; Chen CJ; Hong CF; Hsieh WJ; Chang HT; Chen YS; Lin TW; Hsu HS; Wu CW
    Cancer Res; 2010 Dec; 70(24):10433-44. PubMed ID: 21159654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TALEN-induced disruption of Nanog expression results in reduced proliferation, invasiveness and migration, increased chemosensitivity and reversal of EMT in HepG2 cells.
    Yu AQ; Ding Y; Li CL; Yang Y; Yan SR; Li DS
    Oncol Rep; 2016 Mar; 35(3):1657-63. PubMed ID: 26676719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of NANOG in cancer cells.
    Gong S; Li Q; Jeter CR; Fan Q; Tang DG; Liu B
    Mol Carcinog; 2015 Sep; 54(9):679-87. PubMed ID: 26013997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pluripotency factor NANOG promotes the formation of squamous cell carcinomas.
    Palla AR; Piazzolla D; Alcazar N; Cañamero M; Graña O; Gómez-López G; Dominguez O; Dueñas M; Paramio JM; Serrano M
    Sci Rep; 2015 May; 5():10205. PubMed ID: 25988972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction.
    Alemohammad H; Asadzadeh Z; Motafakker Azad R; Hemmat N; Najafzadeh B; Vasefifar P; Najafi S; Baradaran B
    Life Sci; 2020 Nov; 260():118337. PubMed ID: 32841661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hes1: a key role in stemness, metastasis and multidrug resistance.
    Liu ZH; Dai XM; Du B
    Cancer Biol Ther; 2015; 16(3):353-9. PubMed ID: 25781910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy.
    Rad SM; Bamdad T; Sadeghizadeh M; Arefian E; Lotfinia M; Ghanipour M
    Tumour Biol; 2015 Apr; 36(4):2621-9. PubMed ID: 25464862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncogenic potential of NANOG: An important cancer induction mediator.
    Najafzadeh B; Asadzadeh Z; Motafakker Azad R; Mokhtarzadeh A; Baghbanzadeh A; Alemohammad H; Abdoli Shadbad M; Vasefifar P; Najafi S; Baradaran B
    J Cell Physiol; 2021 Apr; 236(4):2443-2458. PubMed ID: 32960465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
    Shan J; Shen J; Liu L; Xia F; Xu C; Duan G; Xu Y; Ma Q; Yang Z; Zhang Q; Ma L; Liu J; Xu S; Yan X; Bie P; Cui Y; Bian XW; Qian C
    Hepatology; 2012 Sep; 56(3):1004-14. PubMed ID: 22473773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of nanog in tumorigenesis and cancer stem cells.
    Iv Santaliz-Ruiz LE; Xie X; Old M; Teknos TN; Pan Q
    Int J Cancer; 2014 Dec; 135(12):2741-8. PubMed ID: 24375318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway.
    Sun C; Sun L; Jiang K; Gao DM; Kang XN; Wang C; Zhang S; Huang S; Qin X; Li Y; Liu YK
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1099-108. PubMed ID: 23474366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
    Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
    Kenda Suster N; Smrkolj S; Virant-Klun I
    J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NANOG: a promising target for digestive malignant tumors.
    Sun AX; Liu CJ; Sun ZQ; Wei Z
    World J Gastroenterol; 2014 Sep; 20(36):13071-8. PubMed ID: 25278701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.